Literature DB >> 18758419

NOD2/CARD15 polymorphism in patients with rectal cancer.

Jacek Szeliga1, Zbysław Sondka, Marek Jackowski, Joanna Jarkiewicz-Tretyn, Andrzej Tretyn, Marek Malenczyk.   

Abstract

BACKGROUND: Reports published in the past several years have not provided conclusive evidence regarding a relationship between the development of colorectal cancer and NOD2 gene mutations, though some geographic variability has been shown. MATERIAL/
METHODS: The goal of the current project was to analyze the frequency of selected NOD2 gene variants, including P286S, R702W, G908R, and 1007fs, in the Polish population of patients with rectal cancer. Fifty-one rectal cancer patients undergoing treatment were included in the study. As a control group to provide a reference point for NOD2 polymorphism in the population, DNA obtained from cord blood collected from the placenta of 100 patients immediately after parturition was used.
RESULTS: It was found that the aforementioned mutations were more frequent among the colorectal cancer patients and that the presence of the 1007fs variant might also be associated with young patient age.
CONCLUSIONS: The analysis of the material does not allow presenting a conclusive answer as to whether the 1007fs, G908R, and R702W mutations or P268S polymorphism contribute to the development of sporadic colorectal cancer in the Polish population. Patients in some populations could likely benefit from instituting earlier colorectal cancer screening studies following the detection of the 1007fs mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758419

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  8 in total

1.  3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer.

Authors:  Inés Omrane; Amel Mezlini; Olfa Baroudi; Nejla Stambouli; Karim Bougatef; Hager Ayari; Imen Medimegh; Hassen Bouzaienne; Nancy Uhrhammer; Yves-Jean Bignon; Amel Benammar-Elgaaied; Raja Marrakchi
Journal:  Med Oncol       Date:  2014-04-10       Impact factor: 3.064

2.  Bladder cancer survival in patients with NOD2 or CDKN2A variants.

Authors:  Elżbieta Złowocka-Perłowska; Thierry van de Wetering; Aleksandra Tołoczko-Grabarek; Rodney J Scott; Jan Lubiński
Journal:  Oncotarget       Date:  2022-04-22

Review 3.  Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis.

Authors:  Yun Tian; Yi Li; Zhenhua Hu; Daqing Wang; Xiyang Sun; Changshan Ren
Journal:  Int J Colorectal Dis       Date:  2009-09-29       Impact factor: 2.571

4.  Gastric gastrointestinal stromal tumors: clinical features and short- and long-term outcomes of laparoscopic resection.

Authors:  Maciej Stanek; Magdalena Pisarska; Dorota Budzyńska; Anna Rzepa; Michał Pędziwiatr; Piotr Major; Andrzej Budzyński
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-03-26       Impact factor: 1.195

5.  Laparoscopic adrenalectomy: lateral transperitoneal versus posterior retroperitoneal approach - prospective randomized trial.

Authors:  Tomasz Kozłowski; Barbara Choromanska; Piotr Wojskowicz; Kamil Astapczyk; Jerzy Łukaszewicz; Dominika Rutkowski; Jacek Dadan; Alicja Rydzewska-Rosołowska; Piotr Myśliwiec
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-05-05       Impact factor: 1.195

6.  NOD2 polymorphisms associated with cancer risk: a meta-analysis.

Authors:  Jingwei Liu; Caiyun He; Qian Xu; Chengzhong Xing; Yuan Yuan
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

Review 7.  NOD2 Expression in Intestinal Epithelial Cells Protects Toward the Development of Inflammation and Associated Carcinogenesis.

Authors:  Audrey Ferrand; Ziad Al Nabhani; Núria Solà Tapias; Emmanuel Mas; Jean-Pierre Hugot; Frédérick Barreau
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-10-23

8.  Investigating Risk Factors for Complications after Ileostomy Reversal in Low Anterior Rectal Resection Patients: An Observational Study.

Authors:  Mateusz Rubinkiewicz; Jan Witowski; Michał Wysocki; Magdalena Pisarska; Stanisław Kłęk; Andrzej Budzyński; Michał Pędziwiatr
Journal:  J Clin Med       Date:  2019-10-01       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.